pkg

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

DT-2 acetate, a selective cGMP-dependent protein kinase (PKG) inhibitor, is a mouse monoclonal antibody targeting canine thymocytes.DT-2 acetate inhibits PKG-catalyzed phosphorylation, reverses 8-Br-cGMP-induced expansion, and can be used to study immune disorders.

PKG Substrate acetate is a selective substrate for cGMP-dependent protein kinase (PKG).PKG Substrate is a selective substrate for protein kinase G (PKG) with a strong preference for PKG Iα (Km = 59 μM) over PKG II (Km = 305 μM).

PKG inhibitor peptide TFA is an ATP-competitive antagonist of cGMP-dependent protein kinase (PKG) with a K_i value of 86 μM [1].

PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG), showing a strong preference for PKG Iα (Km = 59 µM) over PKG II (Km = 305 µM).

Competitive inhibitor of cGMP-dependent protein kinase (PKG); analog of a substrate peptide corresponding to a phosphorylation site of histone H2B. Competes with synthetic substrates (Ki = 86 mM) but does not inhibit phosphorylation of intact histones by

Vasonatrin Peptide (VNP) TFA, a chimeric compound derived from atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), exhibits venodilating properties reminiscent of CNP, natriuretic effects akin to ANP, as well as unique arterial vasodilating capabilities not characteristic of either parent peptide. Additionally, VNP TFA confers cardioprotection in diabetic ischemia-reperfusion injury by attenuating endoplasmic reticulum (ER) stress through the cGMP-PKG signaling cascade [1] [2] [3].

DT-2 serves as a potent, selective inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 12.5 nM, effectively hindering PKG-catalyzed phosphorylation [1].

DT-3 acetate is a cell-permeable peptide that acts as an inhibitor of protein kinase G (PKGIα), effectively blocking the cGMP-PKG signaling pathway.